Narrow search
Showing 1 - 10 of 10,570
Cover Image
Innovation und Imitation von Bankmarktleistungen : insbesondere im Privatkundengeschäft von Universalbanken
Kaiser, Elisabeth - 1989
Persistent link: https://www.econbiz.de/10004066473
Cover Image
Pioniere überflügeln : neue Produktideen aufgreifen, perfektionieren und vermarkten
Schnaars, Steven P. - 1995
Persistent link: https://www.econbiz.de/10004299162
Cover Image
Generics substitution, bioequivalence standards, and oversight of international pharmaceutical producers: Complex issues facing the FDA
Mathur, Aparna; Bate, Roger - American Enterprise Institute - 2015
In this paper, the authors document the complex issues facing the FDA in assessing the quality of generic drugs. They conclude that increased transparency as well as the updating of FDA bioequivalence standards may be important to overcome some of these challenges.
Persistent link: https://www.econbiz.de/10011273206
Cover Image
Drug Policy 1986
eSocialSciences - 2005
Drug Policy of 1986
Persistent link: https://www.econbiz.de/10009323735
Cover Image
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation
Berndt, Ernst; Aitken, Murray - In: International Journal of the Economics of Business 18 (2011) 2, pp. 177-201
find that once one incorporates substitution to lower priced generics following patent expiration, average price per …
Persistent link: https://www.econbiz.de/10009275875
Cover Image
Competition and the Reference Pricing Scheme for pharmaceuticals
Ghislandi, Simone - In: Journal of Health Economics 30 (2011) 6, pp. 1137-1149
By introducing n (1) firms with infinite cross-price elasticity (i.e. generic drugs), we explore the effects of competition on the optimal pricing strategies under a Reference Pricing Scheme (RPS). A two-stage model repeated infinite number of times is presented. When stage 1 is competitive, the...
Persistent link: https://www.econbiz.de/10010870801
Cover Image
Tendering and decision-making: a case on pharmaceutical products
Dankers, Sven; Vieira, Rui - In: World Review of Entrepreneurship, Management and … 8 (2012) 2, pp. 236-263
In order to contain expenditures for pharmaceuticals, the latest healthcare reforms have focused on decentralising …
Persistent link: https://www.econbiz.de/10010670125
Cover Image
Pharmaceuticals, WTO/TRIPs and Women
Srinivasan, S - eSocialSciences - 2005
This paper looks at the effects of WTO/TRIPS and pharmaceuticals on women. The focus is on the poor and women. The … benefits of health and modern pharmaceuticals. Access to generic low-priced medicines – including medicines for HIV AIDS …
Persistent link: https://www.econbiz.de/10005699276
Cover Image
“BRANDED GENERICS” AS A STRATEGY TO LIMIT CANNIBALIZATION OF PHARMACEUTICAL MARKETS
Ward, Michael R.; Reiffen, David - Department of Economics, College of Business Administration - 2005
This paper demonstrates how, by introducing a generic version of its previously-patented product, a branded firm can influence the equilibrium in the generic segment of the market for the product. This in turn can increase the firm’s profits from selling the branded version. We then use...
Persistent link: https://www.econbiz.de/10005230146
Cover Image
Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization
Duflos, Gautier; Lichtenberg, Frank R. - In: International Review of Law and Economics 32 (2012) 1, pp. 95-109
directly related to marketing expenditure. Changes in market structure due to patent expiration or other factors is likely to … sold during the period 2000–2004 to analyze the impact of changes in market structure (primarily resulting from patent … exactly offset one another, so the net effect of patent expiration on drug utilization is zero. …
Persistent link: https://www.econbiz.de/10010576130